Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab … – Business Wire (press release)
|
Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab …
Business Wire (press release) This agreement builds off Bristol-Myers Squibb and Janssen's previous clinical research collaboration announced in July, 2016 to evaluate Opdivo and Janssen's Live Attenuated Double–Deleted (LADD) Listerial monocytogenes cancer immunotherapy, … |
